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ABSTRACT:  Multiple endocrine neoplasia (MEN) syndromes are characterized by tumors involving 
two or more endocrine glands. Two MEN syndromes have long been known: MEN1 and MEN2, 
caused by germline mutations in MEN1 or RET, respectively. Recently, mutations in CDKN1B, 
encoding the cyclin-dependent kinase (Cdk) inhibitor p27, were identified in patients having a 
MEN1-like phenotype but no MEN1 gene mutations. Currently, the molecular mechanisms 
mediating the role of p27 in tumor predisposition are ill defined.  We here report a novel germline 
missense variant in CDKN1B (c.678C>T, p.P69L) found in a patient with multiple endocrine 
tumors. We previously reported a nonsense p27 mutation (c.692G>A, p.W76X) in two patients 
with MEN1-like phenotype. Functional assays were used to characterize p27P69L and p27W76X 
in vitro. We show that p27P69L is expressed at reduced level and is impaired in both binding to 
Cdk2 and inhibiting cell growth. p27W76X, which is mislocalized to the cytoplasm, can no longer 
efficiently bind Cyclins-Cdks, nor inhibit cell growth or induce apoptosis. In the patient’s tumor 
tissues, p27P69L associates with reduced/absent p27 expression and in one tumor with loss-of-
heterozygosity. Our results extend previous findings of CDKN1B mutations in patients with 
MEN1-related states and support the hypothesis of a tumor suppressor role for p27 in 
neuroendocrine cells.  ©2010 Wiley-Liss, Inc. 
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INTRODUCTION 
We recently demonstrated that germline mutation in Cdkn1b (MIM# 600778), which encodes the p27 cyclin-
dependent kinase (Cdk) inhibitor, causes a multiple endocrine neoplasia (MEN)-like syndrome in the rat (Pellegata 
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et al., 2006). Following this discovery, we identified a germline heterozygous nonsense mutation at codon 76 
(c.692G>A, p.W76X) of the human CDKN1B gene in several members of a family with a variant of the MEN1 
syndrome, thereby demonstrating that CDKN1B is a tumor susceptibility gene also in humans (Pellegata et al., 
2006). Subsequently, an independent study identified a germline CDKN1B  frameshift mutation at codon 25 
(c.59_77dup, p.K25fs) in a female patient with small-cell neuroendocrine
 cervical carcinoma, Cushing’s disease, 
and hyperparathyroidism (Georgitsi et al., 2007). This mutation was associated with loss-of-heterozygosity (LOH) 
of the wild-type CDKN1B allele in the patient’s cervical carcinoma. Recently, three potentially pathogenic changes 
in  CDKN1B (c.-7G>C; c.283C>T, p.P95S; c.595T>C, p.X199QextX*60) were identified in patients with 
hereditary predisposition to MEN1-like tumors or primary hyperparathyroidism (1ºHPT) (Agarwal et al., 2009). In 
vitro, both c.-7G>C and X199Q variants were expressed at reduced level compared to wild-type p27 (p27wt), 
while p27P95S showed decreased binding affinity for Grb2, an adaptor protein involved in the activation of Ras 
signalling (Moeller et al., 2003). Therefore, CDKN1B mutations, although rare, do occur in patients with MEN1-
related states, the so called MEN4 syndrome (MIM# 610755).  Due to the small number of mutation-bearing 
patients so far reported, the phenotypic features associated to MEN4 are still undefined. Moreover, the limited 
molecular characterization of the naturally-occurring CDKN1B mutations identified  hinders a thorough 
understanding of the role of p27 in neuroendocrine tumor predisposition. 
The aim of our study was to search for new CDKN1B mutations and, if found, to functionally characterize them 
in vitro. We report here a novel CDKN1B mutation found in a patient with multiple endocrine tumors. Functional 
analysis of two mutated p27 proteins (the novel we identified and one we previously reported) regarding 
subcellular localization, protein binding and degradation kinetic, growth suppression and apoptosis are presented.  
 
METHODS 
Patients and DNA analysis 
The study was approved by the Ethics Committee of the University of Ferrara, Italy and informed written 
consent was
  obtained from all patients. Twenty-seven Italian patients displaying a MEN1-like phenotype 
(hyperparathyroidism, neuroendocrine tumors, pituitary adenoma), but lacking a MEN1 gene mutation, were 
screened for mutations in CDKN1B (GenBank entry NM_004064.3) as previously reported (Pellegata et al., 2006). 
To determine the frequency of the c.678C>T allelic variant found in an Italian patient we obtained and analyzed 
unrelated control DNA samples from the Institute of Human Genetics, Helmholtz Zentrum München, which 
comprise 370 healthy Germans (KORA Study Group) (Filipiak et al., 2001). Loss of heterozygosity (LOH) 
analysis was performed as previously reported (Shyla et al., 2010) using the chromosome 12p markers D12S391, 
D12S358, and D12S1580.  Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. 
 
 
Plasmid constructs and antibodies 
The two described mutations were introduced by site-directed mutagenesis (Quikchange II Site-Directed 
Mutagenesis Kit, Stratagene) in the wild-type human CDKN1B cDNA cloned in a pEYFP backbone, kindly 
provided by J. Slingerland (University of Miami, FL). Primary antibodies used were: anti-p27 (clone 57) and anti-
GFP tag (BD Biosciences); anti-Skp2 (H-345); anti-Cdk2 (D-12); anti-Cdk4 (C-22); anti-Cyclin D1 (H-295); anti-
Cyclin E (M-20); anti-α-tubulin (all from Santa Cruz Biotechnology).  
 
Cell culture, transfections, drug treatments 
HeLa and MCF7 cell lines were respectively maintained in DMEM or RPMI 1640 media supplemented with 
10% fetal bovine serum, 20 mM L-glutamine, 100 units/ml of penicillin
 G sodium, and 100 µg/ml streptomycin 
(all Invitrogen). The GH3 cell line was maintained in F-12K medium supplemented with 15% horse serum, 2.5% 
fetal bovine serum, 20 mM L-glutamine, 100 units/ml of penicillin
 G sodium, and 100 µg/ml streptomycin.  Identification and Characterization of Germline CDKN1B Mutations    E1827 
 
For p27 half-life determination in exponentially growing cells, cycloheximide (CHX, Sigma-Aldrich, 25 μg/ml) 
was added to the cells for the indicated times.  
Transfections were carried out as already reported (Pellegata et al., 2006). When establishing stable 
transfectants, GH3 cells were selected by adding 0.4 mg/ml G418 to the culture medium for 2-3 weeks and 
individual colonies picked and expanded in presence of G418.  
 
RNA interference 
For RNAi studies, short interfering RNA (siRNA) duplexes specific for SKP2 (n=4; siGenome SMARTpool, 
Dharmacon) and KPC1 (n=2; ID 133486, 133487 Ambion) and scrambled siRNA (Ambion) were obtained and 
transfected into MCF7 cells using X-tremeGENE reagent (Roche) together with 0.03 µg of plasmid DNA.  
 
Protein extraction, immunoblotting and immunoprecipitations  
Protein extraction and immunoblotting were carried out as already reported (Pellegata et al. 2006).  
For IP, 500 μg of total protein were incubated with 5 μl of anti-YFP tag antibody (Clontech-Takara Bio Europe) 
and 20 μl of agarose resin (Santa Cruz) overnight at 4°C. For GST-pull down assay, 500 μg of total protein were 
incubated overnight at 4°C with 2 μg of recombinant Cdk2-GST (Abnova) and 20 μl of Glutathione Agarose 
(Santa Cruz).  
 
Intracellular localization and apoptosis assay 
p27 knock-out (-/-) MEFs were obtained from 13 days old embryos upon trypsin digestion for 15 min at 37ºC. 
Cells were grown in DMEM supplemented with 10% fetal bovine serum, 20 mM L-glutamine, 100 units/ml of 
penicillin
 G sodium, and 100 µg/ml streptomycin (all Invitrogen). For localization experiments, MEFs were grown 
on coverslips, transfected and processed for immunocytochemistry as described (Pellegata et al., 2006) with minor 
modifications. For the apoptosis assay, HeLa cells were transfected while exponentially growing on coverslips. At 
24h or 48h post-transfection cells were fixed and nuclei were stained with DAPI.  
 
Clonogenic assay and growth curve 
To examine clonogenic
 activity, GH3 cells were plated (500,000 per well) in 6-well plates and transfected with 
p27wt, p27W76X or p27P69L using Fugene-6 (Roche). The day after the transfection, the cells were diluted 1:6 
and, starting from the day after, selected for 6 weeks by adding 0.4 mg/ml G418 to the culture medium and stained 
with 0.3% crystal violet in
 30% ethanol. Colonies that contained  50 cells were scored.  
p27W76X GH3 stable clones, and untrasfected GH3 cells were plated in duplicate (100,000 per well) in 12-well 
plate, in full medium plus 400 μg/ml G418. The number of cell was counted every two days over a 9 day-period 
using a cell counter.  
 
Immunohistochemistry 
The two described mutations were introduced by site-directed mutagenesis in the wild-type human CDKN1B 
cDNA cloned into the pEYFP (YFP, yellow fluorescent protein) backbone. Immunohistochemistry were 
performed using a monoclonal anti-p27 antibody (BD Biosciences) as already reported (Pellegata et al., 2006). 
. 
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RESULTS 
Germline genetic changes and clinical presentation 
We screened the genomic DNA of 27 patients for CDKN1B germline changes and found a previously 
unreported variant at codon 69 (c.678C>T, p.P69L) in patient FL, a 79-year-old Caucasian female (Fig. 1A). This 
change was not reported in the single nucleotide polymorphism (SNP) database and was not observed in 370 
unrelated healthy Caucasian controls, confirming that it is neither a polymorphism nor a rare variant. This patient 
presented with bilateral multiple lung metastases of bronchial carcinoid and type 2 diabetes mellitus. A sellar 
magnetic resonance imaging (MRI) revealed a pituitary microadenoma. Clinical work-up did not display any 
alteration in pituitary hormone levels, indicating the presence of a non functioning pituitary microadenoma. This 
patient had a history of endocrine and non-endocrine malignancies: at age 67 she was admitted for surgical 
resection of multiple typical bronchial carcinoids and a subcutaneous epigastric lipoma, and she was subjected to 
left parathyroidectomy because of a parathyroid adenoma causing 1ºHPT. At age 64 a total thyroidectomy had 
been performed due to a papillary thyroid carcinoma with neck lymphnode metastases (pT1bN1M0). The patient 
had no family history of endocrine tumors. Her relatives refused to undergo genetic testing and their phenotype 
could not be determined. 
 
Functional characterization 
In our previous work we identified a heterozygous nonsense mutation at codon 76 (W76X) in a proband with 
GH-secreting pituitary adenoma and 1ºHPT, and in her sister displaying renal angiomyolipoma (Pellegata et al., 
2006). Upon transfection into normal rat fibroblasts, a Myc-tagged p27W76X protein localized to the cytoplasm 
(Pellegata et al., 2006). Although the renal tumor showed no p27 expression we have now detected p27W76X 
expression in the normal kidney of the mutation-positive woman, where it localizes to the cytoplasm. 
To investigate which functional properties of p27wt are affected by P69L and W76X changes, we generated 
plasmid vectors that expressed both p27 mutants as fusion proteins with the YFP tag located at the N-terminus 
(Connor et al., 2003). Transfection of these constructs in MCF7, HeLa and the p27-negative GH3 pituitary 
adenoma cells confirmed the expression of the fusion proteins in vitro and showed that p27P69L is consistently 
expressed at reduced level compared to p27wt in all cell lines (Fig. 1B). 
Following transfection of exponentially growing p27-/- mouse embryonal fibroblasts (to avoid any possible 
interaction with endogenous p27), p27P69L localized mainly to the nucleus, like p27wt (Fig. 1C), although there 
was a higher proportion of cytoplasmic localization (average of YFP-positive cells showing cytoplasmic 
localization of the transfected p27P69L protein: 22.6%) compared to p27wt (average of YFP-positive cells 
showing cytoplasmic localization of the transfected p27wt protein: 8.2%).  As expected, p27W76X was 
cytoplasmic (Fig. 1C). 
p27P69L is consistently expressed at lower steady-state level compared to p27wt. This could be due to 
enhanced protein degradation, the mechanism responsible for p27 down-regulation in many human tumors 
(Pagano et al., 1995; Loda et al., 1997). Exponentially growing MCF7 cells transfected with p27wt, p27P69L or 
p27W76X were incubated with Cycloheximide (CHX) to block new protein synthesis and analyzed at different 
time points thereafter. Up to 8h post-treatment we observed no change in p27wt and p27W76X amount, while 
p27P69L showed reduced expression after 6h (Fig. 2A). This indicates that p27P69L is degraded slightly faster 
than p27wt.  
siRNA-mediated knock-down of the ubiquitin ligases that mediate p27wt degradation (i.e. SKP2, which acts in 
the nucleus in G1-S, and KPC1, which works in early G1 in the cytoplasm) (Carrano et al., 1999; Kamura et al., 
2004) showed that either both these degradation pathways, or just KPC1, play a role also in the degradation of 
p27P69L and p27W76X, respectively (since p27W76X is cytoplasmic, we only tested the effect of KPC1 knock-
down) (Fig. 2B). Co-transfection of the p27 proteins with scrambled siRNA confirmed the specificity of the 
siSKP2 and siKPC1 molecules (Fig. 2C).  Identification and Characterization of Germline CDKN1B Mutations    E1829 
 
 
 
 
 
Figure 1. Characterization of the P69L and W76X mutations in p27. A, 
Sequence chromatograms showing the novel nucleotide change identified in 
patient FL compared to a control normal individual. B, Expression of the 
p27W76X and p27P69L mutant proteins 24h after transfection of MCF7 cells. 
Western blotting (WB) was performed with a monoclonal anti-p27 antibody. C, 
Localization of the p27 proteins. Asynchronously growing p27-negative MEFs 
were transiently transfected with the different YFP fusion constructs. Cells 
were fixed 24h later and nuclei were counterstained with DAPI. Cells were 
examined for direct YFP fluorescence. D, p27P69L does not associate with 
Cdk2. Lysates obtained upon transfection of HeLa with p27wt or p27P69L 
were incubated with purified GST-Cdk2 protein. Following GST pull-down, 50 
μgr of the original lysate (Input) and the entire pull-down (GST-Cdk2) were 
analyzed by Western blotting (WB) with antibodies against p27 or Cdk2. 
 
Considering the crystal structure of the p27-CyclinA-Cdk2 protein complex, the P69L change affects one of the 
six amino acids involved in the direct binding to Cdk2 (Russo et al., 1996). To verify whether this mutation indeed 
alters the binding of p27 to Cdk2, we performed Cdk2 pull-down assays using HeLa cells transiently-transfected 
with p27P69L or control p27wt. Associated p27 proteins were detected by immunoblotting. While p27wt binds 
Cdk2, p27P69L does not bind to the kinase (Fig. 1D).   
p27W76X retains most of the cyclin/Cdk binding domain of p27 (aminoacids 28 to 90), therefore it could bind 
to and sequester in the cytoplasm the canonical p27 partners: Cyclins E and D1, Cdk2 and Cdk4. Upon 
transfection of proliferating HeLa cells, we immunoprecipitated (IP) p27W76X and detected interacting Cyclins 
and Cdks by immunoblotting with specific antibodies. A minimal fraction of p27W76X binds to Cyclin D1, while 
there is no association with the other molecules (Fig. 3A). Similar results were also obtained using GH3-derived 
clones stably and constitutively expressing p27W76X (see below), demonstrating that the lack of association with 
partner proteins is not due to transient p27W76X expression nor to interference by endogenous p27wt. 
p27 is a negative regulator of cell cycle progression, and its loss is associated with disease progression and 
unfavourable outcome in many cancer types (Chu et al., 2008). To determine the effect of P69L and W76X 
mutations on cell growth, we performed a clonogenic assay using p27-negative GH3 cells. The results showed that 
p27wt inhibits the growth of these cells while p27W76X does not. p27P69L was less efficient than p27wt at 
suppressing cell growth (Fig. 3B).  E1830  Molatore et al. 
 
 
 
Figure 2. Degradation kinetics of the p27W76X and p27P69L mutant proteins and 
pathways of degradation.  A, p27P69L is slightly more unstable than p27wt. 
Asynchronously growing MCF7 cells were transiently transfected with the different 
constructs and 24h later treated with CHX for the indicated times. Western blotting 
(WB) was performed using an anti-p27 antibody. The transfected (Tx) exogenous p27 
proteins and the endogenous (Endo) p27 are indicated on the left. To control for equal 
loading the membranes were probed with anti-α-tubulin antibody.  B, Degradation of 
p27W76X and p27P69L is in part mediated by Skp2 and KPC1. MCF7 cells were 
transfected with siRNA against Skp2 or KPC1 together with expression plasmids for 
YFP-p27wt, -p27W76X and –p27P69L and analyzed 48h later by western blotting for 
p27. Transfected (Tx) exogenous p27 proteins and the endogenous (Endo) p27 are 
indicated on the left. C, Scrambled siRNA (Scr. siRNA) has no effect on the 
expression of p27 proteins. Only the transfected proteins are shown. 
 
To verify that the long-term expression of p27W76X has no effect on cell proliferation, we picked and 
expanded several stably-transfected, GH3-derived clones. Selected representative clones were employed for 
growth curves over a period of 9 days. In agreement with the clonogenic assay results, constitutive overexpression 
of p27W76X did not affect GH3 cell proliferation (Fig. 3C).  
Tumor suppression by p27wt works through inhibition of cell proliferation, but also induction of apoptosis in 
some cell types (Katayose et al., 1997). We assessed whether W76X and P69L mutations interfere with the pro-
apoptotic activity of p27wt using HeLa cells as experimental model, as these cells undergo apoptosis upon p27wt 
overexpression (Nickeleit et al., 2008). DAPI staining showed that p27P69L expression induced apoptosis at both 
24h and 48h post-transfection, similarly to p27wt, whereas p27W76X lost this ability (Fig. 3D). 
p27 expression in patients tissues 
We analyzed the expression of p27 in the parathyroid adenoma and one bronchial carcinoid of the patient 
carrying the p27P69L mutation using IHC. Parathyroid adenoma cells showed weak p27 nuclear staining in <1% 
of the tumor cells (interspersed normal endothelial cells served as controls) (Fig. 4C-D). The parathyroid adenoma 
of a mutation-negative control individual exhibited strong p27 nuclear positivity in virtually all cells. A bronchial 
carcinoid of the P69L mutation-positive patient showed virtually no p27 staining when compared to a bronchial 
carcinoid of a mutation-negative individual (Fig. 4E-F). To determine the cause of the reduced p27 expression Identification and Characterization of Germline CDKN1B Mutations    E1831 
 
level in the tumors of this patient, we extracted DNA from tumor and adjacent normal cells and performed LOH 
analysis by amplifying three microsatellite markers flanking the p27 locus (at position 12,76 Mb on chromosome 
12p): D12S391 (12,34 Mb), D12S358 (12,53 Mb) and D12S1580 (13,23 Mb). We observed LOH for the 2 
informative microsatellite markers near the p27 locus in the carcinoid, but not in the parathyroid adenoma (Fig. 
4G). 
 
 
 
Figure 3. Effect of the p27 mutations on protein binding, cell growth and 
apoptosis. A, Asynchronously growing HeLa cells were transfected with 
p27W76X and collected 24h later. Five hundred microgr of the lysate were 
immunoprecipitated (IP) o.n. with the anti-YFP antibody. Fifty microgr of the 
original lysate (Input) and the entire IP (IP YFP) were analyzed by Western 
blotting (WB) with antibodies against the indicated proteins. B, p27-negative 
GH3 cells were transfected with the indicated expression plasmids and then 
selected in G418-containing media for 3 weeks. Colonies were stained and 
counted. The values represent the mean of 2 independent experiments (each 
consisting of 6 separate plates) ±SD. C, Growth curves of representative GH3-
derived clones expressing p27W76X. At day 1 and day 9 cells were lysed and 
total proteins were analyzed by Western blotting (WB). Values are the mean of 2 
independent experiments ±SD. D, p27wt, p27W76X and p27P69L fusion 
proteins were transiently transfected into HeLa cells and 48h later stained with 
DAPI. Cells positive for YFP (=transfected) and showing chromatin 
condensation (=apoptotic) were counted and expressed as the percentage of the 
YFP-positive cells without features of apoptosis (Y axis). The values represent 
the average of 6 independently-transfected plates ±SD. 
 
 
 
DISCUSSION 
Our current study confirms and extends previous findings concerning the presence of CDKN1B germline 
mutations in a sub-set of patients with multiple endocrine tumors. We identified a novel germline missense E1832  Molatore et al. 
mutation in a patient with multiple endocrine and non-endocrine malignancies. Based on few recent studies the 
incidence of CDKN1B mutations in patients with a MEN1-related phenotype is estimated to be 1.5%-2.8% 
(Georgitsi et al., 2007; Agarwal et al., 2009). In our patient cohort the incidence was slightly higher (1/27; 3.7%). 
The identification of additional mutation-positive cases will allow to more precisely assess the contribution of 
CDKN1B mutations to the MEN4 syndrome. 
Functional in vitro characterization of the newly identified mutation (P69L), as well as of the W76X change, 
identified an altered molecular phenotype for both encoded proteins.  
The P69L mutation affects an amino acid located in the Cdk2 binding domain of the protein (aminoacids 52-93) 
and this change is predicted with a high degree of confidence to reduce by more than 55% the hydrophobicity of 
the region (http://www.expasy.org/spdbv/), thereby dramatically altering the environmental conditions necessary 
for binding to the kinase. Our studies demonstrated that indeed this variant does not bind to Cdk2. The 
CyclinE/Cdk2 complex is a very important target of p27 and this binding is crucial for p27-mediated regulation of 
G1 to S phase cell cycle progression (Sherr and Roberts, 1999). Indeed, the inability of p27P69L to bind to Cdk2 
associates with impaired growth suppression of GH3 neuroendocrine tumor cells in vitro.  
We observed extremely reduced/absent p27 expression in the patient’s tumors (parathyroid, bronchial 
carcinoid). This goes beyond the low expression level of p27P69L in vitro and suggests that both the wt and 
mutant allele are expressed at reduced level. Thus, p27P69L retains characteristics which are incompatible with 
sustained cell proliferation. In the carcinoid, lack of p27 expression was associated to LOH. LOH had also been 
observed in the tumor of the patient carrying the p27K25fs mutation (Georgitsi et al., 2007). The observation that 
in several non-endocrine human tumors somatic biallelic inactivation of CDKN1B is exceedingly rare led to the 
hypothesis that p27 is a dose-dependent (haploinsufficient) tumor suppressor (Philipp-Staheli et al., 2001), as 
formally demonstrated in mice (Fero et al., 1998). In contrast, p27 might function as a canonical tumor suppressor 
in neuroendocrine cells. Further studies on mutation-positive patients will help clarify this issue. 
The patient carrying the P69L mutation shows a relatively late age at onset of endocrine disease. The few 
patients so far reported who carry germline CDKN1B mutations show variable age at onset. The two probands 
carrying the W76X or the c.59_77dup, p.K25fs mutation developed tumors at relatively young age (36 and 45 
years of age, respectively), while all other carriers showed a clinical phenotype at age 50 or older. We speculate 
that the age at onset of the mutation-carriers might be related to how severely the CDKN1B mutation alters the p27 
sequence and likely its function, which would in turn provide stronger selective advantage and lead to cell 
expansion. 
The W76X mutation prevents the encoded p27 protein from entering the nucleus, the cell compartment where 
p27 exerts its function as a cell cycle inhibitor, and indeed p27W76X can no longer inhibit the growth of GH3 
cells both by clonogenic assay and by stable expression. Moreover, p27W76X has lost the pro-apototic function of 
p27wt. This is in agreement with reports showing that cells with cytoplasmic p27 are resistant to apoptosis, but can 
become sensitive upon relocalization of the protein to the nucleus (Short et al., 2008). Interestingly, the truncated 
p27W76X protein is stable and can be detected in vitro upon transfection but also, and more significantly, in the 
patient’s normal kidney tissue by immunohistochemistry. Although mutated alleles encoding for truncated 
peptides tend to be unstable and often the encoded peptides are not detected, it has been demonstrated that p27 
deletion mutants comprising only the N-terminus of the protein can be expressed in vitro (Müller et al., 2000; 
Fuster et al., 2010). 
Although the W76X mutation alters several p27 functions, the only tumor tissue of a mutation-positive patient 
available for analysis showed no p27 immunoreactivity (Pellegata et al., 2006) while the truncated protein was 
present in the patient’s normal tissue. This indicates that this mutation possesses functions that are detrimental to, 
or no longer needed by, neuroendocrine tumor cells and therefore selected against during tumor progression. These 
functions might affect still unidentified mechanisms of p27 action and deserve further evaluation.  
Studies on naturally-occurring CDKN1B mutations will help us understand the link between p27 and 
neuroendocrine tumor predisposition, a prerequisite to offer in the future personalized care to the families carrying 
such mutations. 
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Figure 4. Expression of p27P69L and p27W76X in patient tissues. A-F, 
Immunohistochemical staining with an anti-p27 specific antibody. A-B, Staining of 
the normal kidney tissue from the W76X mutation-positive patient who developed 
renal angiomyolipoma (A), and from a normal control individual (B). The patient with 
the germline p27 mutation shows cytoplasmic staining in the renal tubules, whereas 
the normal individual only shows nuclear p27 immunoreactivity in some tubules. C-
D, Staining of the parathyroid tumor from the P69L mutation-positive patient (C) and 
of a similar tumor from a sporadic mutation-negative patient (D). The p27 
immunoreactivity of the tumor cells in the mutation-positive patient is dramatically 
reduced compared to the interspersed endothelial cells (indicated by arrows in the 
Inset). E-F, Staining of one bronchial carcinoid from the P69L mutation-positive 
patient (E) and of a similar tumor from a sporadic patient without mutation in p27 (F). 
There is virtually lack of p27 immunoreactivity of the tumor cells of the mutation-
positive patient compared to the interspersed endothelial cells (indicated by an arrow 
in the Inset). Bar, 50 μM. Original magnification: A-F, 200X; Insets, 400X. G, LOH 
analysis of the tissues of the P69L mutation-positive patient for 3 microsatellite 
markers adjacent to the p27 locus. PT, parathyroid tumor; Carc N, normal tissue 
adjacent to the bronchial carcinoid; Carc T, bronchial carcinoid (tumor tissue).  
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